Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.
Type:
Grant
Filed:
January 19, 2005
Date of Patent:
July 6, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Montse Llinas-Brunet, Murray Bailey, Punit K. Bhardwaj, Francois Bilodeau, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
Abstract: The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
Type:
Grant
Filed:
September 2, 2004
Date of Patent:
June 29, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Andreas Zophel, Horst Johann Ahorn, Birgit Jung, Renate Konopitzky, Karl-Heinz Heider, Norbert Kraut, Peter Seither, Thomas Waerner, Hartmut Beug, Martin Jechlinger, Ido M. Tamir, Andreas Weith, Stefan Gruenert
Abstract: Glucopyranosyl-substituted benzonitrile derivatives as defined herein, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
Type:
Grant
Filed:
February 14, 2007
Date of Patent:
June 29, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Matthias Eckhardt, Frank Himmelsbach, Peter Eickelmann, Achim Sauer, Leo Thomas
Abstract: The invention relates to compounds of general formula 1 wherein n, A, B, D, L, R1, R2, R3 and R4 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Type:
Grant
Filed:
May 10, 2005
Date of Patent:
June 29, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Matthias Grauert, Thierry Bouyssou, Philipp Lustenberger, Steffen Breitfelder, Andreas Schnapp, Michael P. Pieper, Klaus Rudolf, Georg Speck
Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
Type:
Grant
Filed:
December 16, 2005
Date of Patent:
June 22, 2010
Assignee:
Boehringer Ingelheim Pharmaceuticals, Inc.
Inventors:
Daniel Kuzmich, Darren DiSalvo, John Robinson Regan, David S. Thomson
Abstract: The invention relates to the use of selective phosphodiesterase 9A (PDE9A) inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory.
Type:
Grant
Filed:
August 11, 2003
Date of Patent:
June 15, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Frank-Gerhard Böβ, Christina Erb, Martin Hendrix, Marja van Kampen, Frank Wunder
Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.
Type:
Grant
Filed:
June 20, 2007
Date of Patent:
June 15, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.
Type:
Grant
Filed:
October 22, 2007
Date of Patent:
June 15, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Abstract: The invention relates to a new process for preparing modified lactose mixtures, these lactose mixtures per se and compositions of medicaments for powder inhalation consisting of one or more micronised active substances and the modified lactose according to the invention.
Type:
Grant
Filed:
September 21, 2005
Date of Patent:
June 15, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Bernd Wilhelm Mueller, Hartwig Andreas Steckel, Inga-Lis Timmermann, Michael Trunk
Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
Type:
Grant
Filed:
January 4, 2008
Date of Patent:
June 8, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
Abstract: The present invention relates to new substituted thiophene-2-carboxylic acid amides of general formula wherein A, and R1 to R8c are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.
Type:
Grant
Filed:
May 10, 2005
Date of Patent:
June 8, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Roland Pfau, Henning Priepke, Kai Gerlach, Wolfgang Wienen, Annette Schuler-Metz, Herbert Nar, Sandra Handschuh, Georg Dahmann
Abstract: The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient. The other excipient is preferably an amino acid, a peptide and/or a mono-, di- and/or oligosaccharide, wherein the oligosaccharide may be a second 1,4 O-linked saccharose derivative, provided that this is different from the first.
Type:
Grant
Filed:
May 2, 2005
Date of Patent:
June 1, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Stefan Bassarab, Karoline Bechtold-Peters, Richard Fuhrherr, Wolfgang Friess, Patrick Garidel, Torsten Schultz-Fademrecht
Abstract: A locking tensioning mechanism for a miniaturised high pressure generator is disclosed, which mechanism will allow delivery of a set volume of a liquid, and the volume to be delivered by a high pressure generator can be altered subsequently by adjusting one of the stops of the spring component, which locking tensioning mechanism may be used in a high pressure generator for producing an inhalable aerosol or in a needleless injector for injecting a volume of a liquid into animal or plant tissue.
Type:
Grant
Filed:
July 1, 2005
Date of Patent:
June 1, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Gilbert Wuttke, Michael Schyra, Andreas Fiol, Joachim Eicher
Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Type:
Grant
Filed:
February 21, 2007
Date of Patent:
June 1, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co., KG
Inventors:
Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Frank Buettner, Claudia Heine, Philipp Lustenberger, Christoph Hoenke, Klaus Rudolf
Abstract: Disclosed are hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]Amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide: processes for preparing them and their use as pharmaceutical compositions with antiproliferative activity.
Type:
Grant
Filed:
August 4, 2005
Date of Patent:
June 1, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Guenter Linz, Peter Sieger, Gerd F. Kraemer, Rolf Herter, Matthias Hoffmann, Werner Rall, Rolf Schmid
Abstract: The invention relates to crystalline forms of 1-chloro-4-(?-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
Type:
Grant
Filed:
April 21, 2006
Date of Patent:
May 25, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Frank Himmelsbach, Sandra Schmid, Hans-Juergen Martin, Matthias Eckhardt, Martin Schuehle
Abstract: Disclosed are new dihydropteridinones of the formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings provided herein, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.
Abstract: Dihydrothienopyrimidines of formula 1 and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
Type:
Grant
Filed:
February 19, 2009
Date of Patent:
May 25, 2010
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Christoph Hoenke, Birgit Jung, Domnic Martyres, Peter Nickolaus, Pascale Pouzet
Abstract: The present invention relates to a spray-dried powder and method for its manufacture. A spray dried powder containing a pharmaceutical active substance and one or more 1,4 O-linked saccharose derivatives chosen from the compounds: 1,4 O-linked D-gal-saccharose (lactosucrose), 1,4 O-linked D-glu-saccharose (glucosyl sucrose) or 1,4 O-linked glu-glu-saccharose (maltosyl sucrose). Preferred combinations are such that they contain glucosyl and maltosyl sucrose.
Type:
Grant
Filed:
May 2, 2005
Date of Patent:
May 25, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Stefan Bassarab, Karoline Bechtold-Peters, Richard Fuhrherr, Wolfgang Friess, Patrick Garidel, Torsten Schultz-Fademrecht
Abstract: Racemates, diastereolsomers and optical isomers of a compound of formula (I): wherein B is H, a C6 or C10 aryl, C7-16 aralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with C1-6 alkyl; C1-6 alkoxy; C1-6 alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6 alkyl; amido; or (lower alkyl)amide; or B is an acyl derivative of formula R4—C(O)—; a carboxyl of formula R4—O—C(O)—; an amide of formula R4—N(R5)—C(O)—; a thioamide of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5 is H or C1-6 alkyl; and Y is H or C1-6 alkyl; R3 is C1-8 alkyl, C3-7 cycloalkyl, or C4-10 alkylcycloalkyl, all optionally substituted with hydroxy, C1-6 alkoxy, C1-6 thioalkyl, amido, (lower alkyl)amido, C6 or C10 aryl, or C7-16 aralkyl; R2 is CH2—R20, NH—R20, O—R20 or S—R20, wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21, or R20 is a C6
Type:
Grant
Filed:
May 12, 2008
Date of Patent:
May 25, 2010
Assignee:
Boehringer Ingelheim Canada Ltd.
Inventors:
Montse Llinas-Brunet, Murray D. Bailey, Dale R. Cameron, Elise Ghiro, Nathalie Goudreau, Marc-Andre Poupart, Jean Rancourt, Youla S. Tsantrizos, Anne-Marie Faucher, Teddy Halmos, Dominik M. Wernic